^
Association details:
| Biomarker: | EGFR exon 19 deletion + KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
Excerpt:
Of particular note is a patient with both an EGFR exon 19 deletion and a KRAS mutation; this patient did well with erlotinib therapy, achieving stable disease for 25.8 months.
DOI:
10.1158/1078-0432.CCR-09-0888
